Bromo-deaza-SAH: a potent and selective DOT1L inhibitor.

Chemical inhibition of proteins involved in chromatin-mediated signaling is an emerging strategy to control chromatin compaction with the aim to reprogram expression networks to alter disease states. Protein methyltransferases constitute one of the protein families that participate in epigenetic control of gene expression, and represent a novel therapeutic target class. Recruitment of the protein lysine methyltransferase DOT1L at aberrant loci is a frequent mechanism driving acute lymphoid and myeloid leukemias, particularly in infants, and pharmacological inhibition of DOT1L extends survival in a mouse model of mixed lineage leukemia. A better understanding of the structural chemistry of DOT1L inhibition would accelerate the development of improved compounds. Here, we report that the addition of a single halogen atom at a critical position in the cofactor product S-adenosylhomocysteine (SAH, an inhibitor of SAM-dependent methyltransferases) results in an 8-fold increase in potency against DOT1L, and reduced activities against other protein and non-protein methyltransferases. We solved the crystal structure of DOT1L in complex with Bromo-deaza-SAH and rationalized the observed effects. This discovery reveals a simple strategy to engineer selectivity and potency towards DOT1L into the adenosine scaffold of the cofactor shared by all methyltransferases, and can be exploited towards the development of clinical candidates against mixed lineage leukemia.

[1]  N. Pannu,et al.  REFMAC5 for the refinement of macromolecular crystal structures , 2011, Acta crystallographica. Section D, Biological crystallography.

[2]  Yonghong Xiao,et al.  Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. , 2011, Cancer cell.

[3]  M. Erion,et al.  Adenosine kinase inhibitors. 1. Synthesis, enzyme inhibition, and antiseizure activity of 5-iodotubercidin analogues. , 2000, Journal of medicinal chemistry.

[4]  Matthieu Schapira,et al.  Catalytic site remodelling of the DOT1L methyltransferase by selective inhibitors , 2012, Nature Communications.

[5]  Vincent B. Chen,et al.  Correspondence e-mail: , 2000 .

[6]  R. Breaker,et al.  Molecular-recognition characteristics of SAM-binding riboswitches. , 2006, Angewandte Chemie.

[7]  K. O. Elliston,et al.  Chemogenetic Analysis of Human Protein Methyltransferases , 2011, Chemical biology & drug design.

[8]  R. Trievel,et al.  Calmodulin methyltransferase is an evolutionarily conserved enzyme that trimethylates Lys-115 in calmodulin. , 2010, Nature communications.

[9]  Jennifer L. Martin,et al.  SAM (dependent) I AM: the S-adenosylmethionine-dependent methyltransferase fold. , 2002, Current opinion in structural biology.

[10]  Matthieu Schapira,et al.  Structural Chemistry of Human SET Domain Protein Methyltransferases , 2011, Current chemical genomics.

[11]  Tim J. Wigle,et al.  Conformational Adaptation Drives Potent, Selective and Durable Inhibition of the Human Protein Methyltransferase DOT1L , 2012, Chemical biology & drug design.

[12]  Wei Hong,et al.  Toward the development of potent and selective bisubstrate inhibitors of protein arginine methyltransferases. , 2010, Bioorganic & medicinal chemistry letters.

[13]  J. Hess,et al.  The pathogenesis of mixed-lineage leukemia. , 2012, Annual review of pathology.

[14]  S. French,et al.  On the treatment of negative intensity observations , 1978 .

[15]  Jian Jin,et al.  An allosteric inhibitor of protein arginine methyltransferase 3. , 2012, Structure.

[16]  Regina Z. Cer,et al.  IC50-to-Ki: a web-based tool for converting IC50 to Ki values for inhibitors of enzyme activity and ligand binding , 2009, Nucleic Acids Res..

[17]  Valérie Campagna-Slater,et al.  Structural Chemistry of the Histone Methyltransferases Cofactor Binding Site , 2011, J. Chem. Inf. Model..

[18]  A. Brunger.  Free R value: a novel statistical quantity for assessing the accuracy of crystal structures. , 1992 .

[19]  DOT1L, the H3K79 methyltransferase, is required for MLL-AF9-mediated leukemogenesis. , 2011, Blood.

[20]  Yuan Yao,et al.  Selective inhibitors of histone methyltransferase DOT1L: design, synthesis, and crystallographic studies. , 2011, Journal of the American Chemical Society.

[21]  S. Knapp,et al.  Structure and functional characterization of the atypical human kinase haspin , 2009, Proceedings of the National Academy of Sciences.

[22]  A. W. Schüttelkopf,et al.  PRODRG: a tool for high-throughput crystallography of protein-ligand complexes. , 2004, Acta crystallographica. Section D, Biological crystallography.

[23]  Yuan Yao,et al.  Synthesis and Structure−Activity Relationship Investigation of Adenosine-Containing Inhibitors of Histone Methyltransferase DOT1L , 2022 .

[24]  Lars Bullinger,et al.  MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. , 2011, Cancer cell.

[25]  P. Emsley,et al.  Features and development of Coot , 2010, Acta crystallographica. Section D, Biological crystallography.

[26]  Yi Zhang,et al.  Structure of the Catalytic Domain of Human DOT1L, a Non-SET Domain Nucleosomal Histone Methyltransferase , 2003, Cell.

[27]  F. Seela,et al.  7-Functionalized 7-deazapurine β-d and β-l-ribonucleosides related to tubercidin and 7-deazainosine: glycosylation of pyrrolo[2,3-d]pyrimidines with 1-O-acetyl-2,3,5-tri-O-benzoyl-β-d or β-l-ribofuranose , 2007 .

[28]  F. Niesen,et al.  The use of differential scanning fluorimetry to detect ligand interactions that promote protein stability , 2007, Nature Protocols.

[29]  Dino Moras,et al.  Functional insights from structures of coactivator‐associated arginine methyltransferase 1 domains , 2007, The EMBO journal.

[30]  C. Arrowsmith,et al.  Fluorescence-Based Methods for Screening Writers and Readers of Histone Methyl Marks , 2012, Journal of biomolecular screening.